News stories about Trevena (NASDAQ:TRVN) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trevena earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 48.6689857374409 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Zacks Investment Research Upgrades Trevena (TRVN) to “Buy” (americanbankingnews.com)
- BC tightening up highway maintenance contracts (e-know.ca)
- Province has no plan to replace Greyhound in Northern BC (cbc.ca)
- Active Mover – Trevena, Inc., (NASDAQ: TRVN) (stocktradingmedia.com)
- Trevena, Inc. (TRVN) trend is considered pessimistic as stock price is -7.85% below from 50 SMA (analystrecommendation.com)
Trevena stock traded down $0.03 during trading hours on Friday, reaching $1.63. 825,168 shares of the stock were exchanged, compared to its average volume of 876,465. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.71 and a current ratio of 3.71. The company has a market cap of $107.12, a P/E ratio of -1.35 and a beta of -0.52. Trevena has a 52-week low of $1.34 and a 52-week high of $3.64.
TRVN has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of Trevena from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research report on Saturday, January 20th. Oppenheimer restated a “buy” rating on shares of Trevena in a research report on Thursday, March 22nd. Finally, HC Wainwright upped their price objective on shares of Trevena to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $7.06.
COPYRIGHT VIOLATION WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/04/06/trevena-trvn-getting-somewhat-positive-media-coverage-analysis-shows/2037493.html.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.